Add To Watchlist
Share URL
Ascendis Pharma A/S
ASND: NasdaqGSLowest reading is at 37 out of 100. All scores are out of 100.
In Short
About The Company
CEO
Mr. Jan Moller Mikkelsen
Market Cap
14.84 Billion USD
Sector
Healthcare
Website
https://ascendispharma.comLast Update
27/09/2026, 17:26:10
Description
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Read More
Strongest readings
- ✔Altman-Z score of 9.03 sits above the distress range
- ✔Financial health is strong (health score 78 out of 100)
- ✔Debt is low at 0.31 times equity
- ✔Estimated fair value sits 57.22% above the current price
- ✔Return on capital employed of 13.41% is above the market average of 10.00%
Weakest readings
- ✘Share count has been rising at 1.57% per year
Key Figures
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Price / earnings (TTM) | 16.67x | 19.60x | |
| ✔ | Margin of safety (DCF) | 57.22% | 17.95% | |
| ✔ | Revenue growth (5y average) | 25.51% | 10.97% | |
| ✘ | Dividend yield (TTM) | 0.00% | 1.85% | |
| ✘ | Share count, per year | 1.57% | 0.00% | |
| ✔ | Return on capital employed | 13.41% | 10.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Valuation
37 / 100Priced above the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Price / earnings | 16.67x | 19.60x | |
| ✘ | Free cashflow yield | 2.57% | 4.70% | |
| Price / earnings growth | N/A | 1.50x | ||
| Price / book | 10.33x | — | ||
| ✔ | Margin of safety | 57.22% | 17.95% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔Estimated intrinsic value of 354.69 USD is above the current price of 225.60 USD
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Estimated Fair Value: 31 USD ✘
Current Price: 225.6 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.
Growth
63 / 100Growing faster than the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Revenue growth | 25.51% | 10.97% | |
| ✘ | Earnings growth | -68.43% | 14.48% | |
| ✔ | Cashflow growth | 3233.67% | 12.35% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Health
78 / 100Balance sheet covers its obligations.
Measured on Leverage and capital, Funding and liquidity, Earnings quality.
| Status | Metric | Value | Reading | Threshold |
|---|---|---|---|---|
| ✔ | Altman-Z score | 9.03 | 3.00 | |
| ✘ | Piotroski score | 3.00 | 5.00 | |
| ✔ | Debt / equity | 0.31x | 0.80x | |
| ✔ | Current ratio | 2.99x | 1.00x | |
| ✔ | Interest coverage | 17.23x | 2.50x | |
| ✔ | Free cashflow / debt | 0.60x | 0.15x | |
| ✔ | Debt / capital | 0.24x | 1.00x |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Management
73 / 100Returns on capital are at or above the market.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Return on equity | 14.41% | 15.00% | |
| ✔ | Return on capital employed | 13.41% | 10.00% | |
| Return on assets | 9.05% | — | ||
| Free cashflow return on capital | 14.87% | — | ||
| Return on capital, 5y change | N/A | 0.00% | ||
| ✘ | Share count, per year | 1.57% | 0.00% | |
| ✘ | Share count, recent | 2.24% | 0.00% | |
| Realized buyback return | N/A | 0.00% | ||
| ✔ | Goodwill erosion / equity | 0.00% | 2.00% | |
| Price volatility, 5 year | 40.61% | — |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔New shares were issued while the value score was 37 out of 100
Analysts
not enough data| Status | Metric | Value | Reading | Neutral |
|---|---|---|---|---|
| Analyst opinion score | N/A | 50 |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Financial History
Annual figures across the full reporting history we hold.
Market Peers
ASND
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
See 35+ Years Annual ReportsOther Information
Company Name
Ascendis Pharma A/S
Currency
USD
Beta
Vol Avg
640576
Ceo
Mr. Jan Moller Mikkelsen
Cik
0001612042
Cusip
Exchange
NasdaqGS
Full Time Employees
1189
Industry
Biotechnology
Sector
Healthcare
Ipo Date
Address
Tuborg Boulevard 12
City
Hellerup
State
Country
Denmark
Zip
2900
Phone
45 70 22 22 44
Analysis Last Updated
27/09/2026, 17:26:10
Financial data compiled from SEC EDGAR filings and Yahoo Finance.